134307-72-5

Basic information

• Product Name: Carbamic acid, [2-[(methylsulfonyl)oxy]ethyl]-, phenylmethyl ester
• CAS NO: 134307-72-5
• Molecular Formula: C11H15NO5S
• Molecular Weight: 273.31
• Mol File: 134307-72-5.mol
• Article Data: 24

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [2-[(methylsulfonyl)oxy]ethyl]-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [2-[(methylsulfonyl)oxy]ethyl]-, phenylmethyl ester(134307-72-5)
• EPA Substance Registry System: Carbamic acid, [2-[(methylsulfonyl)oxy]ethyl]-, phenylmethyl ester(134307-72-5)

Safety Data

• Hazardous Substances Data: 134307-72-5(Hazardous Substances Data)

Upstream product

• 141-43-5 ethanolamine 
• 124-63-0 methanesulfonyl chloride 
• 501-53-1 benzyl chloroformate 
• 77987-49-6 benzyl 2-hydroxyethylcarbamate 

Downstream Products

• 146552-66-1 benzyl (2-azidoethyl)carbamate 
• 100861-84-5 N²-benzyloxycarbonyl-N¹,N¹-diethyl-1,2-ethanediamine 
• 53844-02-3 benzyl N-(2-bromoethyl)carbamate 
• 17400-34-9 (3-aminopropyl)carbamic acid benzyl ester hydrochloride 
• 595544-64-2 2-{4-[2-(2-Oxo-2-pyrrolidin-1-yl-ethyl)-2H-pyrazol-3-yl]-phenoxy)-ethyl-carbamic Acid Benzyl Ester 
• 595544-49-3 (2-{4-[2-(2-Oxo-2-pyrrolidin-1-ylethyl)-oxazol-4-yl]-phenoxy}-ethyl)-carbamic Acid Benzyl Ester 
• 72080-83-2 2-benzyloxycarbonylaminoethylamine 
• 134307-73-6 <1-¹³C>-3-Benzyloxycarbonylaminopropionitrile 
• 204061-35-8 N¹⁵-cholesteryloxycarbonyl-3,7,12-triaza-N^1,3,12-tri(phenylmethoxycarbonyl)pentadecane-1,15-diamine 
• 204061-26-7 C₅₂H₇₈N₄O₆ 
• 204061-23-4 C₅₁H₇₆N₄O₆ 
• 204061-12-1 (2-Benzyloxycarbonylamino-ethyl)-[3-(tert-butyl-diphenyl-silanyloxy)-propyl]-carbamic acid benzyl ester 
• 204061-20-1 {2-[(3-Azido-propyl)-benzyloxycarbonyl-amino]-ethyl}-carbamic acid benzyl ester 
• 142253-68-7 {2-[Benzyloxycarbonyl-(3-hydroxy-propyl)-amino]-ethyl}-carbamic acid benzyl ester 

Relevant articles and documents

Discovery of New Imidazo[2,1- b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising in Vitro and in Vivo Anti-melanoma Activity

BRAF is an important component of MAPK cascade. Mutation of BRAF, in particular V600E, leads to hyperactivation of the MAPK pathway and uncontrolled cellular growth. Resistance to selective inhibitors of mutated BRAF is a major obstacle against treatment of many cancer types. In this work, a series of new (imidazo[2,1-b]thiazol-5-yl)pyrimidine derivatives possessing a terminal sulfonamide moiety were synthesized. Pan-RAF inhibitory effect of the new series was investigated, and structure-activity relationship is discussed. Antiproliferative activity of the target compounds was tested against the NCI-60 cell line panel. The most active compounds were further tested to obtain their IC50 values against cancer cells. Compound 27c with terminal open chain sulfonamide and 38a with a cyclic sulfamide moiety showed the highest activity in enzymatic and cellular assay, and both compounds were able to inhibit phosphorylation of MEK and ERK. Compound 38a was selected for testing its in vivo activity against melanoma. Cellular and animal activities are reported.

Anticancer profile and anti-inflammatory effect of new N-(2-((4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine sulfonamide derivatives

A new series of N-(2-((4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine sulfonamide derivatives 11a-o were designed and synthesized based on our previous works. The new series was tested for its anticancer and anti-inflammatory effects. The anticancer profile of

Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies

A series of imidazothiazole derivatives possessing potential activity against melanoma cells were investigated for molecular mechanism of action. The target compounds were tested against V600E-B-RAF and RAF1 kinases. Compound 1zb is the most potent agains